Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.62 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.62 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.61 |
| ▸ | LTA4H | P09960 | 2/20 | 0.54 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.53 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | MMP13 | P45452 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.48 |
| ▸ | HTT | P42858 | 3/20 | 0.47 |
| ▸ | TEAD4 | Q15561 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16114401 | 0.89 | LMNA (0.75) | LMNATDP1CYP19A1LTA4HCYP11B1 | |
| SCHEMBL27968872 | 0.85 | LMNA (0.69) | LMNATDP1CYP19A1LTA4HCYP11B1 | |
| SCHEMBL30535283 | 0.85 | LMNA (0.82) | LMNATDP1CYP19A1LTA4HCYP11B1 | |
| SCHEMBL676142 | 0.85 | LMNA (0.82) | LMNATDP1CYP19A1LTA4HCYP11B1 | |
| SCHEMBL11107948 | 0.84 | LMNA (0.62) | LMNATDP1CYP19A1LTA4HCYP11B1 | |
| SCHEMBL21345924 | 0.83 | CYP3A4 (0.57) | CYP19A1LTA4HCYP11B1CYP11B2KMT2A | |
| SCHEMBL29500180 | 0.83 | LMNA (0.72) | LMNATDP1CYP19A1LTA4HCYP11B1 | |
| SCHEMBL78141 | 0.83 | LMNA (0.72) | LMNATDP1CYP19A1LTA4HCYP11B1 | |
| Potassium SCHEMBL6776357 | 0.83 | LMNA (0.78) | LMNATDP1CYP19A1LTA4HCYP11B1 | |
| SCHEMBL20176876 | 0.82 | LMNA (0.60) | LMNATDP1CYP19A1LTA4HCYP11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 136 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102149677-A | Biaryl aminotetralines | HOFFMANN LA ROCHE | 2011-08-10 | — | — | CN | claimed |
| EP-3326715-B1 | OXALIC ACID MONOAMIDE LIGAND, AND USES THEREOF IN COUPLING REACTION OF COPPER-CATALYZED ARYL HALOGEN SUBSTITUTE | CE PHARM CO LTD (CN) | 2021-09-15 | — | — | EP | disclosed |
| EP-3808740-A1 | ORAL DOSAGE FORMS COMPRISING 4-PHENYL-6-(2,2,2-TRIFLUORO-1-PHENYLETHOXY)PYRIMIDINE-BASED COMPOUNDS AND METHODS OF THEIR USE | TerSera Therapeutics LLC (US) | 2021-04-21 | — | — | EP | disclosed |
| WO-2020255020-A1 | COMBINATION OF HEPATITIS B VIRUS (HBV) VACCINES AND PD-L1 INHIBITORS | Janssen Sciences Ireland Unlimited Company (IE) | 2020-12-24 | — | — | WO | disclosed |
| WO-2020245372-A1 | HETEROCYCLIC IMMUNOMODULATORS AS PDL1 CHECKPOINT INHIBITOR | Janssen Sciences Ireland Unlimited Company (IE) | 2020-12-10 | — | — | WO | disclosed |
| EP-3176159-B1 | 4-PHENYL-6-(2,2,2-TRIFLUORO-1-PHENYLETHOXY)PYRIMIDINE-BASED COMPOUNDS AND METHODS OF THEIR USE | LEXICON PHARMACEUTICALS INC (US) | 2020-10-21 | — | — | EP | disclosed |
| WO-2020141439-A1 | HETEROCYCLIC COMPOUNDS AS MUTANT IDH INHIBITORS | INTEGRAL BIOSCIENCES PRIVATE LIMITED (IN) | 2020-07-09 | — | — | WO | disclosed |
| US-20190352276-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | JOINT STOCK COMPANY "BIOCAD" (RU) | 2019-11-21 | — | — | US | disclosed |
| EP-3549934-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | Celgene CAR LLC (BM) | 2019-10-09 | — | — | EP | disclosed |
| WO-2019173507-A1 | ANTIBACTERIAL AGENTS : ARYLALKYLCARBOXAMIDO PHLOROGLUCINOLS | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2019-09-12 | — | — | WO | disclosed |
| US-20070093532-A1 | Benzimidazole carboxamides as raf kinase inhibitors | MERCK PATENT GMBH (DE) | 2007-04-26 | — | — | US | disclosed |
| US-20070093532-A1 | Benzimidazole carboxamides as raf kinase inhibitors | MERCK PATENT GMBH (DE) | 2007-04-26 | — | — | US | disclosed |
| US-20070093529-A1 | Diacylhydrazine derivatives | MERCK PATENT GMBH (DE) | 2007-04-26 | — | — | US | disclosed |
| US-20070055065-A1 | N-sulphonylated amino acid derivatives, method for the production and use thereof | CURACYTE CHEMISTRY GMBH (DE) | 2007-03-08 | — | — | US | disclosed |
| US-20070055065-A1 | N-sulphonylated amino acid derivatives, method for the production and use thereof | CURACYTE CHEMISTRY GMBH (DE) | 2007-03-08 | — | — | US | disclosed |
| US-7176204-B2 | Substituted carboxylic acid derivatives | KYORIN PAHRMACEUTICAL CO., LTD. (JP) | 2007-02-13 | — | — | US | disclosed |
| US-7176204-B2 | Substituted carboxylic acid derivatives | KYORIN PAHRMACEUTICAL CO., LTD. (JP) | 2007-02-13 | — | — | US | disclosed |
| US-20070010560-A1 | angiogenesis, in particular in tumors, restenoses, diabetic retinopathy, macular degenerative disease or rheumatoid arthritis | MERCK PATENT GMBH (DE) | 2007-01-11 | — | — | US | disclosed |
| US-20070010560-A1 | angiogenesis, in particular in tumors, restenoses, diabetic retinopathy, macular degenerative disease or rheumatoid arthritis | MERCK PATENT GMBH (DE) | 2007-01-11 | — | — | US | disclosed |
| WO-2003007954-A2 | SULFONYL ARYL HYDROXAMATES AND THEIR USE AS MATRIX METALLOPROTEASE INHIBITORS | PHARMACIA CORPORATION (US) | 2003-01-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070093532-A1 | Benzimidazole carboxamides as raf kinase inhibitors | BRAF, RAF1, ARAF | LMNA 2964/4885TDP1 2653/4885CYP19A1 2859/4885 |
| US-20070055065-A1 | N-sulphonylated amino acid derivatives, method for the production and use thereof | DNPEP, ANPEP, PEPD | LMNA 854/4885TDP1 2326/4885CYP19A1 1562/4885 |
| US-20070010560-A1 | angiogenesis, in particular in tumors, restenoses, diabetic retinopathy, macular degenerative disease or rheumatoid arthritis | BRAF, RAF1, VEGFA | LMNA 3781/4885TDP1 3048/4885CYP19A1 1832/4885 |
| US-20070093529-A1 | Diacylhydrazine derivatives | BRAF, RAF1, NRAS | LMNA 3800/4885TDP1 1410/4885CYP19A1 1085/4885 |
| US-20190352276-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | BTK, ABL1, CNKSR1 | LMNA 946/4885TDP1 1826/4885CYP19A1 2835/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.